-transparent.png){kind=logo}
Cholinergic muscarinic binding by viable peripheral lymphocytes was assessed by measuring specific binding of the muscarinic antagonist [3H]quinuclidinyl benzylate. After atropine treatment maximal lymphocyte muscarinic binding was increased by about 30%, as it did in the hippocampus of the same rats. Strain-dependent differences in muscarinic binding by peripheral lymphocytes were correlated with similar differences in selective brain regions. Higher muscarinic binding was observed in lymphocytes derived from aged (24 months old) rats. We conclude: atropine treatment causes an increase in lymphocyte muscarinic binding as it does in the brain; strain differences in brain muscarinic binding are paralleled by similar differences in lymphocytes; and in aged rats muscarinic binding capacity by lymphocytes is elevated. The results indicate that circulating lymphocytes may serve as a useful peripheral marker reflecting induced alterations or inherent differences in muscarinic binding.
L Shenkman, and
J M Rabey, and
G M Gilad
January 1988,
Immunopharmacology,
L Shenkman, and
J M Rabey, and
G M Gilad
March 1991,
Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
L Shenkman, and
J M Rabey, and
G M Gilad
January 1987,
Neurobiology of aging,
L Shenkman, and
J M Rabey, and
G M Gilad
June 1978,
Proceedings of the National Academy of Sciences of the United States of America,
L Shenkman, and
J M Rabey, and
G M Gilad
July 1981,
Life sciences,
L Shenkman, and
J M Rabey, and
G M Gilad
May 1974,
Proceedings of the National Academy of Sciences of the United States of America,
L Shenkman, and
J M Rabey, and
G M Gilad
October 1986,
Neuroscience letters,
L Shenkman, and
J M Rabey, and
G M Gilad
January 1988,
Journal of neural transmission,
L Shenkman, and
J M Rabey, and
G M Gilad
February 1975,
Nature,
L Shenkman, and
J M Rabey, and
G M Gilad
March 1982,
Proceedings of the National Academy of Sciences of the United States of America,
